A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Novel Combinations in Participants with Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2023
This article has no abstract
Epistemonikos ID: 89e9caebfbf5793106418ebdb18accfb930fb693
First added on: Jan 23, 2025